We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-8.37%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.28B
AUM Growth
-$1.41B
Cap. Flow
-$1.19B
Cap. Flow %
-22.61%
Top 10 Hldgs %
53.54%
Holding
466
New
23
Increased
24
Reduced
24
Closed
360

Top Buys

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$72.5M
2
LEGN icon
Legend Biotech
LEGN
+$64.3M
3
OSCR icon
Oscar Health
OSCR
+$64.1M
4
DVAX
Dynavax Technologies
DVAX
+$62.6M
5
INDV icon
Indivior Pharmaceuticals
INDV
+$39M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$187M
2
KURA icon
Kura Oncology
KURA
+$106M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$66.5M
4
SGRY icon
Surgery Partners
SGRY
+$57.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$56.2M

Sector Composition

Rank Sector Weight
1 Healthcare 87.97%
2 Industrials 0.23%
3 Consumer Staples 0.01%
4 Energy 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRTC icon
51
iRhythm Holdings
IRTC
$3.69B
$14.1M 0.27%
+156,012
New +$12.3M
CMRX
52
DELISTED
Chimerix, Inc.
CMRX
$13.1M 0.25%
+3,771,342
New +$5.32M
CON
53
Concentra Group Holdings
CON
$4.08B
$12.9M 0.24%
650,000
– –
ZBIO
54
Zenas BioPharma
ZBIO
$2.07B
$12.8M 0.24%
1,562,942
– –
ACCD
55
DELISTED
Accolade Inc
ACCD
$11.9M 0.23%
3,475,000
– –
THRD
56
DELISTED
Third Harmonic Bio
THRD
$10.5M 0.2%
+1,019,700
New +$12.7M
SYRE icon
57
Spyre Therapeutics
SYRE
$8.69B
$10.5M 0.2%
+450,000
New +$13.2M
LUNG icon
58
Pulmonx
LUNG
$51.5M
$10.4M 0.2%
+1,534,763
New +$10.1M
DYN icon
59
Dyne Therapeutics
DYN
$4.24B
$10.3M 0.19%
435,653
– –
NGNE icon
60
Neurogene
NGNE
$691M
$10.2M 0.19%
+448,145
New +$16.7M
GPCR icon
61
Structure Therapeutics
GPCR
$3.46B
$10.1M 0.19%
373,407
-471,000
-56% -$16.7M
CATX icon
62
Perspective Therapeutics
CATX
$322M
$9.37M 0.18%
2,938,754
+120,991
+4% +$988K
FATE icon
63
Fate Therapeutics
FATE
$283M
$5.87M 0.11%
3,555,871
– –
NKTX icon
64
Nkarta
NKTX
$162M
$5.37M 0.1%
2,155,000
– –
CRVS icon
65
Corvus Pharmaceuticals
CRVS
$1.09B
$5.35M 0.1%
+1,000,000
New +$7.47M
CALC icon
66
CalciMedica
CALC
$11.1M
$4.6M 0.09%
1,300,000
+300,000
+30% +$1.05M
HLVX
67
DELISTED
HilleVax
HLVX
$3.9M 0.07%
1,882,654
– –
OMIC
68
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$3.23M 0.06%
166,162
– –
ANNX icon
69
Annexon
ANNX
$841M
$3M 0.06%
583,913
– –
ALEC icon
70
Alector
ALEC
$168M
$2.02M 0.04%
1,066,962
+11,770
+1% +$44.3K
NAMSW icon
71
NewAmsterdam Pharma Warrant
NAMSW
$87.4M
$1.32M 0.03%
92,787
– –
PHGE icon
72
BiomX
PHGE
$2.13M
$1.31M 0.02%
94,085
– –
VTYX
73
DELISTED
Ventyx Biosciences
VTYX
$1.17M 0.02%
534,737
-6,180,764
-92% -$14M
TWST icon
74
Twist Bioscience
TWST
$5.39B
$1.11M 0.02%
23,827
+403
+2% +$18.2K
TOI icon
75
The Oncology Institute
TOI
$519M
$1.04M 0.02%
3,360,052
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2024 Portfolio in Review

As of Q4 2024, Deerfield Management held 466 positions worth $5.28B, down 21% from $6.69B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $1.19B in Q4 2024, closing 360 positions and reducing 24 holdings. Its most notable exit was Kura Oncology, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Deerfield Management opened a new position in Legend Biotech worth $50.5M.

  • Deerfield Management's largest Q4 2024 buy was Legend Biotech: 1,551,718 shares worth $50.5M.
  • Deerfield Management added most to NewAmsterdam Pharma in Q4 2024, an estimated $72.5M increase.
  • Deerfield Management's biggest Q4 2024 reduction was Nuvalent, cutting an estimated $187M.
  • Deerfield Management fully exited Kura Oncology in Q4 2024, selling an estimated $106M.
  • Deerfield Management's ten largest holdings make up 54% of its $5.28B portfolio in Q4 2024.
  • Deerfield Management opened 23 new positions and closed 360 in Q4 2024.
  • Deerfield Management's portfolio value fell 21% quarter-over-quarter to $5.28B.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.